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A diagnosis of a renal 
injury by early biomarkers 




We prospectively studied renal function in 158 patients scheduled for elective cardiac surgery with the use of cardiopul-
monary bypass (CPB).
The patients involved in this study had normal renal function as well as normal function of the left ventricle. The results of 
the study showed a statistically significant increase of early markers of renal injury Alpha-1-Microglobulin (A1M) and Neu-
trophil Gelatinase-Associated Lipocalin (NGAL), which were being traced in the patients’ urine 5 hours and 24 hours after 
CPB. In contrast with the aforementioned early markers, the so-called “classical” markers of renal injury – serum urea and 
creatinine – did not show a statistical significance of value increase after CPB. Using early factors of renal injury A1M and 
NGAL, the study managed to show slight, subclinical injuries of the proximal renal tubules after CPB and cardiac surgeries. 
The value of these factors lies in their early and precise detection of renal injury, which is a significant clinical parameter for 
monitoring renal function, especially after cardiac surgery with the use of CPB.  
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A great number of routine cardiac sur-
geries are carried out with the use of 
a system for cardiopulmonary bypass 
(CPB). The system replaces the function 
of heart and lungs during a surgery. The 
technique of the system is prosperous 
and is adjusted to a great extent to the 
physiological functions of our organi-
sm. In spite of this, CPB has unwanted 
effects upon physiological functions of 
our organism. (1-5), including an effects 
upon possible renal injury. (6-10)
The frequency of acute renal failure after 
cardiac surgeries with the use of CPB is 
between 1 and 5%. The frequency of 
subclinical renal injuries is greater, but 
cannot be proved by routine traditional 
tests for the time being. These traditio-
nal tests are the so-called tests for dia-
gnosis of renal injury, serum urea and 
creatinine, creatinine clearance and 
the analysis of the urine’s sediment. 
(11,12) Initial tubule-interstitial changes 
are revealed with difficulty with the use 
of these traditional tests, although the 
changes can be revealed in greater 
renal injuries. Subclinical renal injuries, 
especially of renal tubules, can be pro-
ved by early markers. (13-15) Two of 
the aforementioned markers are highly 
specific early markers of proximal renal 
tubules injuries: Alpha-1-Microglobu-
lin (A1M) and Neutrophil Gelatinase-
Associated Lipocalin (NGAL), which are 
determined in urine. (16-19)
This paper primarily studied unwanted 
effects of CPB upon renal injury – that 
is, the function of proximal renal tubu-
les. To define renal injury, early markers 
of renal tubules’ injuries in urine (NGAL 
and AIM) were determined. In order to 
compare them, the traditional tests of 
urea and creatinine were determined 
in serum. 
Materials and methods
Under approval by the Ethical Commi-
ttee of the Medical Faculty Zagreb, and 
the Ethical Committee of the Clinical 
Hospital Zagreb, 158 patients sche-
duled for elective cardiac surgery with 
CPB were studied prospectively (with 
previously informed consent) between 
November 2012 to June 2013.
The selected patients had normal renal 
function and normal left ventricular 
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ejection fraction, and had not been 
exposed recently to nephrotoxic drugs 
(including radiographic contrast media, 
antibiotics etc.). Emergency surgery, 
hemodynamic instability, use of inotro-
pes and associated diseases, including 
diabetes mellitus, were considered as 
causes for exclusion. The patients’ 
ages ranged from 18 and 83 years, with 
a mean of 63 years + SD 13.6. 
Patients were pre-medicated with 0.1 
mg/kg morphine sulphate. Anaesthesia 
was induced with fentanyl 20-40 μg/kg, 
ethomidat 10-20 mg and rocuronium 
0.1 mg/kg and was maintained with 
sevoflurane in oxygen, as well as addi-
tional sufentanyl and rocuronium. Moni-
toring was completed after induction 
and included invasive arterial pressure, 
a thermodilution pulmonary artery cat-
heter in some cases, a urinary bladder 
catheter and a transesophageal echo. 
Non-pulsatile CPB was performed with 
a roller pump and membrane oxyge-
nator (“Medtronic Affinity” and “Euro-
set Admiral”) primed with 1600 ml of 
prime solution. The pump flow was 2.2 
L x min-1 x m-2. Moderate hypother-
mia (26-28 °C) was used in all patients. 
Cardioplegic solution was intermittently 
infused. Alpha stat Ph. management 
was used for acid-base management. 
The main arterial pressure during the 
bypass was allowed to vary between 
55-100 mm Hg (mean 73.29 mmHg 
+ SD 7.31). Norepinephrine or nitrogl-
ycerine was used to correct deviations 
beyond this range. Inotropes were not 
used intra-operatively or early post-
operatively in any of the study patients.
Blood and urine samples were obtai-
ned at the following times: 1) baseline 
measurements: blood samples for urea 
and creatinine measurements taken 
between 1 to 2 days before the ope-
ration; urine samples for NGAL and 
A1M were taken after induction of ana-
esthesia. 2) 5 hours post-operatively: 
urine samples for NGAL and A1M. 3) 24 
hours post-operatively: urine samples 
for NGAL and A1M and blood samples 
for urea and creatinine. 4) 48 hours 
post-operatively: blood samples for 
urea and creatinine. Urine was collec-
ted using a Foley catheter. 
Until the determination of the quantity 
of A1M in the laboratory, all the urine 
samples were marked in plastic test 
tubes and were kept in a refrigerator 
at a temperature of -18 °C. A series 
of 50 samples were determined in the 
laboratory. Until the determination of 
the quantity of NGAL in the laboratory 
all the urine samples were marked in 
plastic test tubes and centrifugated. 
After being centrifugated, which lasted 
5 minutes at >400 RCF (Relative cen-
trifugal Force), the supernatant was 
taken and was separated into marked 
plastic test tubes which had been, 
after marking, kept in a refrigerator at 
a temperature of -70 °C. A series of 
80 samples were determined in the 
laboratory. Serum samples were imme-
diately determined in the laboratory 
after being taken and it was not neces-
sary to keep them. Urea concentrations 
were measured by a Kinetic UV test 
with urease (Olympus AU 2700, Japan). 
Serum urea values were expressed in 
mmol/L and the normal value is 2,.8-
8.3 mmol/L. Creatinine concentrations 
were measured by continuous photo-
metry with alcal picrate (Olympus AU 
2700, Japan). Serum creatinine values 
were expressed in μmol/L and the nor-
mal value was 79-125 μmol/L for male 
patients and 63-107 μmol/L for female 
patients. Urine concentration of NGAL 
was measured by the CMIA – Chemilu-
minescent Microparticle Immunoassay 
(Abbot Diagnostic, Architect 1000 SR, 
Wiesbaden, Germany). NGAL values 
were expressed in ng/mL and the nor-
mal value was below 132 ng/mL. Urine 
concentration of A1M was measured by 
Table 1. Descriptive statistics of renal injury markers in urine and serum in a total sample
 N Mean SD Min Max
Percentile
25. Median 75.
A1M before CPB 150 19.74 14.00 5.56 92.76 8.54 17.63 25.72
A1M 5 h after CPB 150 28.25 37.70 5.56 219.00 5.56 14.60 32.48
A1M 24 h after CPB 150 35.75 25.35 5.56 146.00 20.65 31.40 45.30
NGAL before CPB 66 15.87 18.38 1.70 145.70 7.47 11.35 18.18
NGAL 5 h after CPB 66 102.04 342.57 0.00 2305.50 2.68 6.20 15.35
NGAL 24 h after CPB 66 35.26 29.31 1.00 115.00 14.28 23.45 46.60
Urea before CPB 158 6.31 1.83 2.70 12.10 4.90 6.15 7.50
Urea 24 h after CPB 158 5.36 2.19 1.40 12.00 3.70 5.00 6.55
Urea 48 h after CPB 158 5.91 2.64 0.80 16.00 4.00 5.55 7.03
Kreatinin before CPB 158 102.49 20.30 57.00 169.00 89.00 103.00 113.25
Kreatinin 24 h after CPB 158 109.42 25.87 67.00 225.00 90.00 105.00 124.00
Kreatinin 48 h after CPB 158 109.18 30.82 63.00 272.00 87.75 105.00 123.00
A1M, alpha-1-microglobulin; CBP, cardiopulmonary bypass; NGAL, neutrophil gelatinase-associated lipocalin
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the imunonefelometric method (Behring 
Werke, Marburg, Germany). A1M valu-
es were expressed in mg/L and the 
normal value was <15 mg/L.
The data are presented in the tables 
and graphically. Using Kolmogorov-
Smirnovljev’s test, an analysis of the 
normality of data distribution was carri-
ed out. According to the obtained data, 
corresponding non-parameter tests 
were used in a further analysis. Diffe-
rences in dependent measures were 
analysed by Friedman’s test. The level 
of significance was 0.05. The STATISTI-
CA programme support (version 10.0) 
was used in the analysis (www.statsoft.
com). 
Results
Table 1 shows the descriptive statistics 
of renal injury markers. A1M was deter-
mined in all patients and NGAL was 
determined in 66 patients. Urea and 
creatinine were determined in 8 pati-
ents more in contrast with A1M becau-
se in these patients A1M samples were 
incorrectly taken. 
Table 1 shows A1M and NGAL increase 
after ECC in relation to the initial values 
before surgery (that is, before CPB). 
The so-called “classic” renal injury mar-
kers (serum urea and creatinine) do not 
show any dynamics of increase. 
Using Friedman’s test, the statistical 
significance of A1M and NGAL levels 
were determined, depending on time 
dynamics (table 2). 
Table 2 shows the statistical significan-
ce (P <0.001) in both studied markers. 
Using the same test, urea and creatinine 
values do not show a statistically signi-
ficant difference depending on time 
dynamics (for creatinine P = 0.034). 
By studying certain A1M values one 
can notice that they are slightly above 
normal values, thus confirming a slight 
renal injury. NGAL values are not higher 
than normal values. However, one can 
notice their increase, so we can talk 
about a slight subclinical renal injury.
Discussion
All the patients in the study had normal 
renal function before a surgery and 
CPB.
Not a single patient developed acute 
renal failure. By traditional “classic” 
renal injury markers – urea and creatini-
ne – the study did not show renal injury 
caused by CPB. Using early factors of 
renal injury, A1M and NGAL, the study 
showed slight subclinical renal tubular 
injury after CPB and cardiac surgeries. 
The definition of acute kidney injury 
(AKI) is difficult. Results of many studi-
es that investigate biomarkers of renal 
injury are difficult to extend because 
of important differences in AKI defini-
tions, measurement methods, timing, 
population and several possible con-
founding factors. (20) For example, 
A1M and NGAL are markers of tissue 
damage and proximal tubular stress, 
but not of kidney function of glomerular 
filtration rate like creatinine and urine 
output. AKI in cardiac surgery pati-
ents is multifactorial including factors 
such hypovolemia, hypotension, chro-
nic kidney disease and drug toxicity, 
that occur at differential timing before, 
during and after surgery. (21) Today, 
a large number of clinical studies and 
reviews indicate that A1M and NGAL 
should be considered as reliable dia-
gnostic and prognostic biomarkers 
for kidney injury. Reference ranges, 
adjusted for age, gender and ethni-
city, as well as reliable cut-off values 
calculated on large patient populati-
ons, for ruling in and out AKI, are still 
lacking. (22) Ideally, the performance 
of the biomarkers should be tested in 
addition to the clinical and laboratory 
evaluations available in current clinical 
practice. There is a consensus that 
most of the emerging kidney injury bio-
markers may be able to detect injury 
earlier than serum creatinine and urea. 
Biomarker performance is measured 
by assessing the diagnostic or predic-
tive performance based on the actual 
standard, serum creatinine. (23)
Conclusion
The value of the early factors of renal 
tubular injury that were studied lies 
in their early detection of renal injury, 
which is a new additional clinical para-
meter for monitoring renal function, 
especially after cardiac surgeries with 
the use of CPB.








A1M before CPB 150 8.54 17.63 25.72 1.66
100.64 <0.001A1M 5 h after CPB 150 5.56 14.60 32.48 1.70
A1M 24 h after CPB 150 20.65 31.40 45.30 2.64
NGAL before CPB 66 7.47 11.35 18.18 1.85
46.03 <0.001NGAL 5 h after CPB 66 2.68 6.20 15.35 1.50
NGAL 24 h after CPB 66 14.28 23.45 46.60 2.65
A1M, alpha-1-microglobulin; CBP, cardiopulmonary bypass; NGAL, neutrophil gelatinase-associated lipocalin
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